RAB22A and cancer: Therefore, the 1–10 a.a.-iRGD peptide disturbs the Rab22a-NeoF1 binding to both SmgGDS607 and PYK2, and then would in principle diminish lung metastasis in cancer patients who are positive for RAB22A-NeoF1 fusion gene.